中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.027 seconds)

    ＣＴＬＡ４ 및 ＩＬ２１Ｒ 을 포함하는 융합 단백질 및 이를 포함하는 관절염 예방 및 치료용 조성물
    5.
    发明公开
    ＣＴＬＡ４ 및 ＩＬ２１Ｒ 을 포함하는 융합 단백질 및 이를 포함하는 관절염 예방 및 치료용 조성물 有权
    包含CTLA4和IL21R的融合蛋白及其组合物，用于预防或治疗包含其的ARTHRITI

    公开(公告)号：KR1020130031137A

    公开(公告)日：2013-03-28

    申请号：KR1020110094885

    申请日：2011-09-20

    Applicant: 가톨릭대학교 산학협력단 ,  주식회사 와이바이오로직스

    Inventor： 주지현 ,  김영균 ,  강귀영 ,  성경미 ,  유석호 ,  박재은 ,  장명희 ,  김혜난

    IPC: C07K19/00 ,  C12N15/62 ,  A61K38/17 ,  A61P19/02

    Abstract: PURPOSE: A fusion protein is provided to suppress T cell activity and to prevent or treat arthritis. CONSTITUTION: A fusion protein contains CTLA4(cytotoxic T-lymphocyte antigen 4) and IL21R(Interleukin-21 receptor). The fusion protein has an amino acid of sequence number 1. IL21R and CTLA4 have amino acid sequences of sequence numbers 2 and 3, respectively. The fusion protein additionally contains an immunoglobulin Fc region at N-terminal or C-terminal. A transformant is prepared by transforming a host cell with a recombinant vector containing a gene encoding the fusion protein. [Reference numerals] (AA) Stimulation (-); (BB) Stimulation (+); (CC) CTLA4 +IL-21Fc dual target(fusion protein)

    Abstract translation: 目的：提供融合蛋白以抑制T细胞活性和预防或治疗关节炎。 构成：融合蛋白含有CTLA4（细胞毒性T淋巴细胞抗原4）和IL21R（白细胞介素-21受体）。 融合蛋白具有序列号1的氨基酸.IL21R和CTLA4分别具有序列号2和3的氨基酸序列。 融合蛋白另外含有N-末端或C-末端的免疫球蛋白Fc区。 通过用含有编码融合蛋白的基因的重组载体转化宿主细胞来制备转化体。 （附图标记）（AA）刺激（ - ）; （BB）刺激（+）; （CC）CTLA4 + IL-21Fc双靶（融合蛋白）

    메클리진을 포함하는 관절염 예방 및 치료용 조성물
    6.
    发明公开
    메클리진을 포함하는 관절염 예방 및 치료용 조성물 有权
    用于预防和治疗包含MECLIZINE的ARTHRITIS的组合物

    公开(公告)号：KR1020130031128A

    公开(公告)日：2013-03-28

    申请号：KR1020110094862

    申请日：2011-09-20

    Applicant: 가톨릭대학교 산학협력단

    Inventor： 주지현 ,  김영균 ,  강귀영

    IPC: A61K31/496 ,  A61K31/4965 ,  A61P19/02 ,  A61P19/00

    CPC classification number: A61K31/495 ,  C07D241/04 ,  Y10S514/825

    Abstract: PURPOSE: A pharmaceutical composition containing meclizine is provided to protect cartilage and bone tissue and to prevent and treat arthritis. CONSTITUTION: A pharmaceutical composition for preventing and treating arthritis contains a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salt is hydrochloride. The arthritis includes osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, systemic lupus erythematosus, polymyositis, or polymyalgia rheumatic.

    Abstract translation: 目的：提供含麦地利的药物组合物，以保护软骨和骨组织，并预防和治疗关节炎。 构成：用于预防和治疗关节炎的药物组合物含有化学式1的化合物或其药学上可接受的盐。 药学上可接受的盐是盐酸盐。 关节炎包括骨关节炎，类风湿性关节炎，强直性脊柱炎，反应性关节炎，系统性红斑狼疮，多发性肌炎或风湿性多肌痛。

    시트룰린화된 단백질에 특이적인 단클론 항체 및 이를 생산하는 하이브리도마 세포주
    7.
    发明授权
    시트룰린화된 단백질에 특이적인 단클론 항체 및 이를 생산하는 하이브리도마 세포주 有权
    特定蛋白质和其生产的杂交细胞系的单克隆抗体

    公开(公告)号：KR101237002B1

    公开(公告)日：2013-02-25

    申请号：KR1020120054963

    申请日：2012-05-23

    Applicant: 가톨릭대학교 산학협력단

    Inventor： 주지현 ,  김영균 ,  이효주 ,  김주련 ,  정혜린 ,  문수진 ,  강귀영 ,  김인제

    IPC: C07K16/18 ,  C12N5/12 ,  G01N33/53

    CPC classification number: G01N33/564 ,  C12N5/163 ,  G01N2800/102

    Abstract: PURPOSE: A monoclonal antibody which specifically detects proteins with a citrulline residue and a hybridoma cell line are provided to detect citrullinated proteins and to diagnose and treat autoimmune diseases. CONSTITUTION: A monoclonal antibody or an antigen-binding fragment thereof for diagnosing rheumatic arthritis contains a heavy chain variable region with an amino acid sequence of sequence number 3 and a light chain variable region with an amino acid of sequence number 4. The monoclonal antibody or the fragment is produced from a hybridoma(deposit number KCLRF-BP-00276). A method for providing information for diagnosing rheumatoid arthritis comprises a step of measuring antigen-antibody response of citrullinated proteins in a sample. A composition for diagnosing rheumatoid arthritis contains the monoclonal antibody or the fragment. A kit for diagnosing rheumatoid arthritis contains the antibody or the fragment. [Reference numerals] (AA) Cultivating Myeloma cell strain; (BB) Myeloma cell; (CC) Antigen; (DD) Spleen cell; (EE) Fusing in poly(ethylene glycol); (FF) Selecting and cultivating hybrid cells; (GG) Selecting antibody producing cells; (HH) Mass cultivating; (II) Producing clone; (JJ) Freezing; (KK) Thawing; (LL) Inducing tumor; (MM,NN) Antibody

    Abstract translation: 目的：提供特异性检测瓜氨酸残基和杂交瘤细胞系的蛋白质的单克隆抗体，用于检测瓜氨酸化蛋白质并诊断和治疗自身免疫性疾病。 构成：用于诊断风湿性关节炎的单克隆抗体或其抗原结合片段含有具有序列号3的氨基酸序列的重链可变区和具有序列号4的氨基酸的轻链可变区。单克隆抗体或 该片段由杂交瘤（保藏号KCLRF-BP-00276）产生。 用于提供用于诊断类风湿性关节炎的信息的方法包括测量样品中瓜氨酸化蛋白质的抗原 - 抗体应答的步骤。 用于诊断类风湿性关节炎的组合物含有单克隆抗体或片段。 用于诊断类风湿关节炎的试剂盒含有抗体或片段。 （AA）培养骨髓瘤细胞株; （BB）骨髓瘤细胞; （CC）抗原; （DD）脾细胞; （EE）熔融聚（乙二醇）; （FF）选择和培养杂交细胞; （GG）选择产生抗体的细胞; （HH）大规模耕种; （二）生产克隆; （JJ）冷冻; （KK）解冻; （LL）诱导肿瘤; （MM，NN）抗体

    메포민을 포함하는 자가면역질환 예방 및 치료용 조성물
    9.
    发明公开
    메포민을 포함하는 자가면역질환 예방 및 치료용 조성물 有权
    用于预防和治疗包含METFORMIN的自身免疫疾病的组合物

    公开(公告)号：KR1020130031229A

    公开(公告)日：2013-03-28

    申请号：KR1020120104603

    申请日：2012-09-20

    Applicant: 가톨릭대학교 산학협력단

    Inventor： 주지현 ,  김영균 ,  강귀영

    IPC: A61K31/155 ,  A61P19/02 ,  A61P17/00 ,  A61P37/00

    Abstract: PURPOSE: A metformin-containing pharmaceutical composition is provided to suppress Th17 cell differentiation and to prevent and treat autoimmune diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating autoimmune diseases contains a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof. The salt is hydrochloride. The autoimmune disease is caused by Th17 cells and is selected from the group consisting of psoriasis, rheumatic arthritis, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, autoimmunity myocarditis, atopic dermatitis, contact hypersensitivity, inflammatory bowel disease, and periodontal disease.

    Abstract translation: 目的：提供含二甲双胍的药物组合物以抑制Th17细胞分化并预防和治疗自身免疫疾病。 构成：用于预防和治疗自身免疫性疾病的药物组合物含有化学式1的化合物或其药学上可接受的盐。 盐是盐酸盐。 自身免疫性疾病由Th17细胞引起，并且选自牛皮癣，风湿性关节炎，系统性硬化症，系统性红斑狼疮，多发性硬化，自身免疫性心肌炎，特应性皮炎，接触性超敏反应，炎症性肠病和牙周病。

    항-ＶＥＧＦ 항체를 포함하는 자가면역질환 예방 및 치료용 조성물
    10.
    发明公开
    항-ＶＥＧＦ 항체를 포함하는 자가면역질환 예방 및 치료용 조성물 有权
    用于预防和治疗包含抗VEGF抗体的自身免疫疾病的组合物

    公开(公告)号：KR1020130031136A

    公开(公告)日：2013-03-28

    申请号：KR1020110094884

    申请日：2011-09-20

    Applicant: 가톨릭대학교 산학협력단 ,  주식회사 와이바이오로직스

    Inventor： 주지현 ,  김영균 ,  강귀영 ,  성경미 ,  유석호 ,  박재은 ,  장명희 ,  김혜난

    IPC: A61K39/395 ,  A61P37/00

    CPC classification number: A61K39/395 ,  A61K39/3955 ,  A61K2039/505

    Abstract: PURPOSE: An anti-VEGF antibody-containing composition is provided to suppress differentiation of Th17 cell and to prevent and treat autoimmune diseases. CONSTITUTION: A composition for preventing and treating autoimmune diseases contains a monoclonal antibody. The monoclonal antibody comprises: a heave chain variable region containing heavy chain CDR1 with an amino acid sequence of sequence number 5, heavy chain CDR2 with an amino acid sequence of sequence number 6, and heavy chain CDR3 with an amino acid sequence of sequence number 7; and a light chain variable region containing light chain CDR1 with an amino acid sequence of sequence number 8, light chain CDR 2 with an amino acid sequence of sequence number 9, and light chain CDR3 with an amino acid sequence of sequence number 10.

    Abstract translation: 目的：提供含抗VEGF抗体的组合物，以抑制Th17细胞的分化和预防和治疗自身免疫性疾病。 构成：用于预防和治疗自身免疫疾病的组合物含有单克隆抗体。 单克隆抗体包含：含有重链CDR1，序列号5的氨基酸序列的重链可变区，具有序列号6的氨基酸序列的重链CDR2和序列号7的氨基酸序列的重链CDR3 ; 和含有序列号8的氨基酸序列的轻链CDR1，序列号9的氨基酸序列的轻链CDR2和序列号10的氨基酸序列的轻链CDR3的轻链可变区。

Patent Agency Ranking